Manufacturer of Acido D Malico - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex
Manufacturer of Acido D Malico - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:
Product Detail
| Name | Desmopressin |
| CAS number | 16679-58-6 |
| Molecular formula | C46H64N14O12S2 |
| Molecular weight | 1069.22 |
| EINECS Number | 240-726-7 |
| Specific rotation | D25 +85.5 ± 2° (calculated for the free peptide) |
| Density | 1.56±0.1 g/cm3(Predicted) |
| RTECS No. | YW9000000 |
| Storage conditions | Store at 0°C |
| Solubility | H2O:soluble20mg/mL, clear, colorless |
| Acidity coefficient | (pKa) 9.90±0.15 (Predicted) |
Synonyms
MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN
Indications
(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.
(2) Treatment of nocturnal enuresis (patients aged 5 years or older).
(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.
(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.
Treatment of diabetes insipidus
Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.
Product detail pictures:
Related Product Guide:
Our business puts emphasis on the administration, the introduction of talented personnel, as well as the construction of team building, trying hard to further improve the standard and liability consciousness of staff members customers. Our enterprise successfully attained IS9001 Certification and European CE Certification of Manufacturer of Acido D Malico - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Namibia, Norwegian, Victoria, We have now 48 provincial agencies in the country. We also have stable cooperation with several international trading companies. They place order with us and export solutions to other countries. We expect to cooperate with you to develop a larger market.
By Karen from Karachi - 2018.06.03 10:17
As a veteran of this industry, we can say that the company can be a leader in the industry, select them is right.
By Betty from Chile - 2018.02.08 16:45
